{
    "nct_id": "NCT03873493",
    "official_title": "A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia",
    "inclusion_criteria": "* Adequate liver, kidney and hematology function per laboratory values as described in the protocol.\n* Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* Received prior alemtuzumab (unless unsuitable or unavailable).\n* Has no malignancies other than T-PLL that:\n\n  * currently require systemic therapies;\n  * were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or\n  * developed signs of progression after curative treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of or current decompensated cirrhosis including Child-Pugh class B or C, ascites, hepatic encephalopathy, or variceal bleeding.\n* Has human T-cell lymphotropic virus, type 1.\n* Prior allogeneic stem cell transplant within 6 months of study drug administration and requirement for graft versus host therapy.\n* Has an uncontrolled or active infection including severe acute respiratory syndrome- coronavirus-2 (SARS-COV-2).\n* Previously treated with a B-cell lymphoma (BCL)-2 inhibitor.\n* Received a prohibited therapy within the specified time frame as described in the protocol.",
    "miscellaneous_criteria": ""
}